Clinical trials: Glabellar Frown Lines
Moderate to Severe Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
The study objective was to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on…
- Trial name
- NCT00770029
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- 8 sites in United States, Canada
- Volunteers
- 276 people
- Sponsor
- Merz Pharmaceuticals GmbH
Moderate-severe Glabellar Lines
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
Evaluate onset time and safety of improvement effect of each group's forehead wrinkles after 2, 3, 4, 5, 14 days from administration of 20U dosage of DWP450-004 for adult patients who need more than moderate improvement of…
- Trial name
- NCT02568150
- Testing
- Single group, open-label
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Frown Lines
Study Comparing Treatment With Alluzience vs Reconstituted Toxin
This is a Phase IV, open-label, randomized, interventional, two-armed, multi-centre study to investigate subject treatment perception and Investigator treatment experience when using Alluzience or vacuum-dried botulinum…
- Trial name
- STAR (NCT05277337)
- Testing
- Alluzience, powder BoNT-A (BOTOX/Vistabel)
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Galderma R&D
Glabellar Frown Lines
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.
- Trial name
- NCT05217355
- Testing
- MBA-P01 (Botulinum toxin A)
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Medytox Korea
Glabellar Frown Lines
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)
This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of CU-20101 in the treatment of moderate to severe glabellar lines.
- Trial name
- NCT06585696
- Testing
- CU-20101 treatment for Moderate to Severe Glabellar Striae, BOTOX®
- Where
- China
- Volunteers
- 554 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Glabellar Frown Lines
The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines
This study will be conducted in Phase I/II clinical trials. In Phase I, subjects with moderate to severe glabellar lines are enrolled and those who are judged to be eligible for this study will be injected with the "PROTOXIN" at…
- Trial name
- NCT04996810
- Testing
- PROTOXIN, Botox®
- Where
- 2 sites in South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Protox Inc.
Glabellar Frown Lines
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label…
- Trial name
- NCT04143815
- Testing
- MBA-P01 (Botulinum toxin A)
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Medy-Tox
Glabellar Frown Lines
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton).
- Trial name
- Head2Head (NCT00777803)
- Testing
- NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®)), OnabotulinumtoxinA (Vistabel®)
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 381 people
- Sponsor
- Merz Pharmaceuticals GmbH
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
The purpose of this study is to investigate the safety and efficacy of NT 201 (active ingredient: Botulinum (neuro)toxin type A, free from complexing proteins) in the combined treatment of wrinkles in the upper face (Upper Facial…
- Trial name
- ULTRA I (NCT04594213)
- Testing
- NT 201
- Where
- 12 sites in United States
- Volunteers
- 362 people
- Sponsor
- Merz North America, Inc.
Glabellar Frown Lines
Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
This study is intended to evaluate long-term safety and efficacy of MBA-P01 in treatment of glabellar lines.
- Trial name
- NCT05321979
- Testing
- MBA-P01
- Where
- South Korea
- Volunteers
- 253 people
- Sponsor
- Medytox Korea
Glabellar Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
- Trial name
- NCT03014635
- Testing
- Botulinum Toxins, Type A
- Where
- 14 sites in United States, Canada
- Volunteers
- 306 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
NT 201 is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, NT 201 causes local weakening to full paralysis depending on the…
- Trial name
- NCT00430586
- Testing
- Botulinum neurotoxin type A, free of complexing proteins
- Where
- Germany
- Volunteers
- 191 people
- Sponsor
- Merz Pharmaceuticals GmbH
Facial Rhytides, Glabellar Frown Lines
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
This study evaluated the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of forehead lines (facial rhytides) when also administered to frown lines (glabellar rhytides).
- Trial name
- NCT01391299
- Testing
- botulinum toxin Type A, Normal Saline
- Where
- Canada
- Volunteers
- 175 people
- Sponsor
- Allergan
Glabellar Lines
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines.
- Trial name
- NCT00512135
- Testing
- IncobotulinumtoxinA (Xeomin) (20 units)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 801 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
- Trial name
- NCT03014622
- Testing
- Botulinum Toxins, Type A
- Where
- 15 sites in United States
- Volunteers
- 303 people
- Sponsor
- Revance Therapeutics, Inc.
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESS I (NCT02677298)
- Testing
- Botulinum Toxin A
- Where
- 18 sites in United States, Germany and 1 more
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Croma-Pharma GmbH
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II
The aim of this study is to assess the efficacy and safety of BoNT/a-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESS-II (NCT02677805)
- Testing
- Botulinum Toxin A, Botulinum Toxin A - Open Label
- Where
- 7 sites in United States
- Volunteers
- 251 people
- Sponsor
- Croma-Pharma GmbH
Glabellar Frown Lines
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown…
- Trial name
- NCT05320393
- Testing
- PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening.
- Trial name
- NCT00430963
- Testing
- IncobotulinumtoxinA (Xeomin) (20 Units)
- Where
- Germany
- Volunteers
- 256 people
- Sponsor
- Merz Pharmaceuticals GmbH
Glabellar Frown Lines
Subject Satisfaction With AbobutulinumtoxinA Treatment
An interventional Phase 4 study to assess subject satisfaction with abobotulinumtoxinA treatment.
- Trial name
- DREAM (NCT03687736)
- Testing
- AbobotulinumtoxinA
- Where
- 6 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Galderma R&D